We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Affibody and NIH to Develop Molecular In Vivo Imaging Agents

Affibody and NIH to Develop Molecular In Vivo Imaging Agents

Affibody and NIH to Develop Molecular In Vivo Imaging Agents

Affibody and NIH to Develop Molecular In Vivo Imaging Agents

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affibody and NIH to Develop Molecular In Vivo Imaging Agents "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Affibody AB has announced a cooperative agreement with the NCI/NIH on the development of conjugates with Affibody® molecules to be used for in vivo imaging of cancers over-expressing HER2.

The collaboration is a Cooperative Research and Development Agreement (CRADA) with the Radiation Oncology Branch of the National Cancer Institute and builds on Affibody AB's proprietary Affibody® technology and various conjugation systems of the NIH.

The molecules under development are expected to be useful for medical imaging monitoring of patients with cancer diseases that over-express the HER2 protein.

Affibody will design and develop engineered Affibody® molecules specific for HER2, a receptor protein often over-expressed in breast- and ovary cancers, among others.

NCI plans to conjugate the engineered Affibody® molecules with various detection molecules to evaluate them for non-invasive tumor and metastasis visualization.

Medical imaging agents should be highly specific and small, as small size allows for good tissue penetration and rapid clearance from the blood. This renders high contrast images within short time.

Dr. Lars Abrahmsen, Chief Scientific Officer at Affibody, commented, “Affibody® molecules are perfectly suited for imaging agents due to their very small size combined with high specificity for their target.”

“In addition, they can be produced by peptide synthesis which allows for site specific and quantitative incorporation of the tracer in a single chemical process.”

“This increases the sensitivity of the tumor detection as well as facilitates the manufacturing process for clinical grade material.”

Affibody's Chief Executive Officer, Torben Jorgensen said, “We are delighted to be working alongside such a prestigious group in the USA.”

“This collaboration further validates our strategic focus on medical imaging and personalized medicine within the oncology field and ensures that we maintain a leading competitive position in the rapid development of agents for molecular medical imaging.”

“Affibody AB is particularly pleased to be increasing its research and development programs in North America, and to be collaborating with research groups that are working in one of the leading clinical cancer trial centers in the USA,” he added.